EX 103
Alternative Names: EX-103 - Guangzhou Excelmab; EX103Latest Information Update: 16 Jul 2024
At a glance
- Originator Guangzhou Excelmab
- Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
- Research Chronic lymphocytic leukaemia; Rheumatoid arthritis
Most Recent Events
- 31 May 2024 Efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 20 Oct 2023 Efficacy and adverse events data from phase I trial in Non-Hodgkin's lymphoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 14 Sep 2023 Guangzhou Excelmab files an BLA application in China in December 2025 (Guangzhou Excelmab pipeline september 2023)